The purpose of this clinical research study is to evaluate signals of potential clinical benefit of the combination of RDEA3170 and Febuxostat in lowering concentrations of circulating uric acid and thus improving kidney or cardiovascular status of patients with hyperuricemia, albuminuria, and Type 2 diabetes (T2DM).